Weill Cornell Medicine scientists have developed an innovative human neuron model that robustly simulates the spread of tau protein aggregates in the brain-;a process that drives cognitive decline in Alzheimer’s disease and frontotemporal dementia.
FDA rejects motion sickness drug from Defender Pharma
Government-partnered Defender Pharmaceuticals received an FDA rejection Tuesday for its motion sickness prevention drug. “We plan on scheduling a formal meeting with the FDA to
January 31, 2024